AstraZeneca PLC (FRA:ZEG)
Germany · Delayed Price · Currency is EUR | Market Cap | 254.10B |
| Revenue (ttm) | 49.54B |
| Net Income (ttm) | 8.01B |
| Shares Out | n/a |
| EPS (ttm) | 5.13 |
| PE Ratio | 31.72 |
| Forward PE | 18.92 |
| Dividend | 2.91 (1.77%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 93 |
| Average Volume | 233 |
| Open | 161.25 |
| Previous Close | 162.15 |
| Day's Range | 161.25 - 164.70 |
| 52-Week Range | 113.25 - 164.70 |
| Beta | n/a |
| RSI | 65.27 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
AstraZeneca: Oncology Dominance Justifies New All-Time Highs
Walmart to replace AstraZeneca on Nasdaq 100 effective Jan. 20
Walmart (WMT) Joins Nasdaq-100 Index, Replacing AstraZeneca (AZN)
Walmart (WMT) Joins Nasdaq-100 Index, Replacing AstraZeneca (AZN)
Walmart To Join Nasdaq-100 Index As AstraZeneca Exits In January 2026 Reshuffle
(RTTNews) - Nasdaq (NDAQ) announced that Walmart Inc. (WMT) will join the Nasdaq-100 Index (NDX), the Nasdaq-100 Equal Weighted Index (NDXE), and the Nasdaq-100 Ex-Tech Sector Index (NDXX). The inclus...
Walmart to Join Nasdaq-100, Replacing AstraZeneca
Walmart to Join Nasdaq-100, Replacing AstraZeneca
Healthy Returns: What to expect from pharma at the JPM conference
At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN) concluded the recent trading session at $94.01, signifying a -1.21% move from its prior day's close.
AstraZeneca names Rick Suarez head of US biopharmaceuticals unit
AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the drugmaker's previously announced $50 billion research, development and manufac...
AstraZeneca: Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
Appointment supports AstraZeneca's $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030 AstraZeneca has named Rick R. Suarez Senior Vice President, US President and...
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the Company’s previously announced $50 b...
Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit. Suarez will lead the execution of the C...
BostonGene Corporation: BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development
AI-powered platform to predict patient safety and efficacy profiles, unlocking precision-driven oncology development BostonGene, the developer of the leading AI foundation model for tumor and immu...
BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with AstraZeneca, a global, scienc...
AstraZeneca's (AZN) Saphnelo Shows Promising Phase III Results
AstraZeneca's (AZN) Saphnelo Shows Promising Phase III Results
AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial
On Tuesday, AstraZeneca Plc (NASDAQ: AZN) released complete results from the Phase 3 TULIP-SC trial of a subcutaneous (SC) administration of anifrolumab versus placebo in participants aged 18 to 70 y...
AMD and its Partners Share their Vision for "AI Everywhere, for Everyone" at CES 2026
News Highlights AMD provided an early look at its "Helios" rack-scale platform, the blueprint for yotta-scale AI infrastructure, built on AMD Instinct MI455X GPUs and AMD EPYC "Venice" CPUs designed f...
AstraZeneca (AZN) Dropped from Goldman Sachs' European Conviction List
AstraZeneca (AZN) Dropped from Goldman Sachs' European Conviction List
CVS, Astra, Cardinal to continue record setting rally into 2026: Barron’s
CVS Health (CVS) stock, AstraZeneca)AZN) stock and Cardinal Health (CAH) stock in focus as Barron's expect thier 2025 rally to continue into new year. Read more here.
These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.
With a 58% gain, CVS Health had its best year since 1982—and it wasn't the only strong performer.
The Zacks Analyst Blog Highlights Berkshire Hathaway, AstraZeneca, Intel, Kingsway Financial and BK Technologies
Berkshire Hathaway headlines new Zacks research reports, with strong insurance performance, cash strength and diversified growth drivers.
Top Stock Reports for Berkshire Hathaway, AstraZeneca & Intel
Berkshire Hathaway's shares have edged past its industry, backed by insurance growth, rising float, strong cash and expanding investments, including Japan.
Judge Halts US Drug Discount Overhaul, Blocks 340B Rebate Plan
A federal judge on Monday temporarily blocked the U.S. administration’s planned 340B Rebate Model Pilot Program, finding that regulators likely failed to meet basic administrative law requirements bef...
China’s rising biotech clout on show in flurry of billion-dollar licensing deals
Chinese drugmakers have signed a late-year burst of out-licensing agreements with overseas partners, underlining China’s growing role as a source of novel medicines as multinational pharma groups hunt...
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
Validea Detailed Fundamental Analysis - AZN
Below is Validea's guru fundamental report for ASTRAZENECA PLC (ADR) (AZN). Of the 22 guru strategies we follow, AZN rates highest using our Twin Momentum Investor model based on the published strateg...